%0 Journal Article
%A Teibo, John Oluwafemi
%A Silveira, Roberta Maraninchi
%A Silvestrini, Virginia Campos
%A Archiolli, Izadora
%A PaulaMasson, Ana
%A de Morais, Beatriz Pereira
%A Schmidt, Dayane
%A Dos Santos, Matheus Henrique
%A Ferreira, Germano Aguiar
%A Thomé, Carolina Hassibe
%A Helm, Dominic
%A Nirujogi, Raja Sekhar
%A Alessi, Dairo Renato
%A Picanço-Castro, Virginia
%A de Souza, Lucas Eduardo Botelho
%A Faça, Vitor Marcel
%T Proteomics analysis reveals early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer.
%J Journal of proteomics
%V 321
%@ 1874-3919
%C New York, NY [u.a.]
%I Elsevier
%M DKFZ-2025-01562
%P 105507
%D 2025
%Z Volume 321, 30 October 2025, 105507Journal of Proteomics
%X Chimeric antigen receptor T-cell (CAR-T) therapy is at the forefront of the field of cell immunotherapy. In this study, we generated an anti-CD19 CAR-Jurkat T cell line using a locally produced second-generation anti-CD19 CAR construct, which allowed us to analyse early proteomic changes that are crucial for comprehending the signalling pathways and mechanism of action of this CAR-T cell. SILAC-heavy tagged RAJI B-cells and anti-CD19 CAR-Jurkat T-cells were co-cultured for ten minutes. The proteomic profiles were acquired via DIA methodology on the Orbitrap Astral LC-MS/MS platform. The proteome was extensively covered, resulting in about 8800 protein identifications at 1 
%K CAR-T cell (Other)
%K Early Signalling event (Other)
%K Hematological Cancer (Other)
%K Molecular effectors (Other)
%K Proteomics (Other)
%K SILAC (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40716489
%R 10.1016/j.jprot.2025.105507
%U https://inrepo02.dkfz.de/record/303211